DE60045240D1 - Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma - Google Patents
Antikörper gegen tnf alpha zur therapie von steroidresistentem asthmaInfo
- Publication number
- DE60045240D1 DE60045240D1 DE60045240T DE60045240T DE60045240D1 DE 60045240 D1 DE60045240 D1 DE 60045240D1 DE 60045240 T DE60045240 T DE 60045240T DE 60045240 T DE60045240 T DE 60045240T DE 60045240 D1 DE60045240 D1 DE 60045240D1
- Authority
- DE
- Germany
- Prior art keywords
- steroid
- antibodies
- therapy
- tnf alpha
- resistant asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26095399A | 1999-03-02 | 1999-03-02 | |
US46569199A | 1999-12-17 | 1999-12-17 | |
PCT/US2000/005163 WO2000051637A1 (en) | 1999-03-02 | 2000-03-01 | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60045240D1 true DE60045240D1 (de) | 2010-12-30 |
Family
ID=26948290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60045240T Expired - Lifetime DE60045240D1 (de) | 1999-03-02 | 2000-03-01 | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
Country Status (10)
Country | Link |
---|---|
US (3) | US20010021381A1 (de) |
EP (1) | EP1159003B1 (de) |
JP (2) | JP2002538170A (de) |
AT (1) | ATE488250T1 (de) |
AU (1) | AU756677B2 (de) |
CA (1) | CA2364026C (de) |
DE (1) | DE60045240D1 (de) |
DK (1) | DK1159003T3 (de) |
PT (1) | PT1159003E (de) |
WO (1) | WO2000051637A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115804821A (zh) * | 2022-12-19 | 2023-03-17 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
EP1594540A1 (de) * | 2003-02-11 | 2005-11-16 | Boehringer Ingelheim International GmbH | Neue pharmazeutische zusammensetzungen auf basis von anticholinergika und anti-tnf-antikörpern |
EP2010214A4 (de) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis |
PE20080980A1 (es) * | 2006-10-12 | 2008-09-02 | Genentech Inc | Anticuerpos anti-linfotoxina alfa |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
ES2616728T3 (es) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedimientos y composiciones para facilitar la regeneración |
CA2827609A1 (en) * | 2011-02-17 | 2012-11-15 | Nestec S.A. | Assays for detecting autoantibodies to anti-tnf.alpha. drugs |
CA2961603C (en) * | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
BR112019021471A2 (pt) | 2017-04-13 | 2020-05-12 | Siwa Corporation | Anticorpo monoclonal humanizado de produto final da glicação avançada |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US4822776A (en) * | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US6309640B1 (en) * | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US6419927B1 (en) * | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0288088B1 (de) * | 1987-04-24 | 1994-03-09 | Teijin Limited | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung |
US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
JPH06506120A (ja) * | 1991-03-18 | 1994-07-14 | ニューヨーク・ユニバーシティ | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
DE4139733A1 (de) * | 1991-11-28 | 1993-06-03 | Schering Ag | Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren |
ATE155043T1 (de) * | 1992-10-08 | 1997-07-15 | Kennedy Inst Of Rheumatology | Behandlung von autoimmun- und entzundungskrankheiten |
EP0671936A1 (de) * | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | Behandlung der insulinresistenz bei mit übergewicht verbundenem type ii-diabetes mittels antogonisten gegen die funktion von tnf-g(a) |
GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
US20050255104A1 (en) * | 1993-01-29 | 2005-11-17 | Centocor, Inc. | Methods of treating psoriasis using anti-TNF receptor fusion proteins |
DE122009000074I1 (de) * | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
SE9302490D0 (sv) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
DE69721548T2 (de) * | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
GB9702088D0 (en) * | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
TR199902562T2 (xx) * | 1997-04-15 | 2000-02-21 | Farmaceutisk Laboratorium Ferring A/S | De�i�tirilmi� TNF alfa molek�lleri |
AU7345798A (en) * | 1997-05-12 | 1998-12-08 | Kennedy Institute Of Rheumatology, The | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
-
2000
- 2000-03-01 DE DE60045240T patent/DE60045240D1/de not_active Expired - Lifetime
- 2000-03-01 PT PT00912065T patent/PT1159003E/pt unknown
- 2000-03-01 CA CA2364026A patent/CA2364026C/en not_active Expired - Fee Related
- 2000-03-01 AT AT00912065T patent/ATE488250T1/de active
- 2000-03-01 EP EP00912065A patent/EP1159003B1/de not_active Expired - Lifetime
- 2000-03-01 DK DK00912065.0T patent/DK1159003T3/da active
- 2000-03-01 JP JP2000602303A patent/JP2002538170A/ja active Pending
- 2000-03-01 AU AU33861/00A patent/AU756677B2/en not_active Ceased
- 2000-03-01 WO PCT/US2000/005163 patent/WO2000051637A1/en active IP Right Grant
-
2001
- 2001-01-12 US US09/759,412 patent/US20010021381A1/en not_active Abandoned
- 2001-08-28 US US09/942,075 patent/US20020119152A1/en not_active Abandoned
-
2006
- 2006-03-02 US US11/366,724 patent/US20060222646A1/en not_active Abandoned
-
2010
- 2010-09-01 JP JP2010195818A patent/JP2011006464A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115804821A (zh) * | 2022-12-19 | 2023-03-17 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
CN115804821B (zh) * | 2022-12-19 | 2024-05-14 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
AU3386100A (en) | 2000-09-21 |
EP1159003B1 (de) | 2010-11-17 |
JP2002538170A (ja) | 2002-11-12 |
WO2000051637A1 (en) | 2000-09-08 |
US20020119152A1 (en) | 2002-08-29 |
DK1159003T3 (da) | 2011-02-07 |
US20060222646A1 (en) | 2006-10-05 |
CA2364026A1 (en) | 2000-09-08 |
CA2364026C (en) | 2012-08-21 |
PT1159003E (pt) | 2011-02-22 |
AU756677B2 (en) | 2003-01-23 |
EP1159003A1 (de) | 2001-12-05 |
ATE488250T1 (de) | 2010-12-15 |
US20010021381A1 (en) | 2001-09-13 |
JP2011006464A (ja) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60045240D1 (de) | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma | |
NO963280L (no) | Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer | |
DE60143535D1 (de) | Humane antikörper gegen cd40 | |
CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
UA111707C2 (uk) | Застосування виділеного анти-tnf-альфа антитіла людини | |
BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
DE69433666D1 (de) | ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma | |
CY1112858T1 (el) | Θεραπευτικο ανθρωπινο αντι-ιl-1r1 μονοκλωνικο αντισωμα | |
DE69934515D1 (de) | Humanisierte monoklonale integrin antikörper | |
ATE429922T1 (de) | Topische gel-abgabesysteme zur behandlung von hauterkrankungen | |
PL374865A1 (en) | Treatment of tnf alpha related disorders | |
ATE525075T1 (de) | Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen | |
ATE534635T1 (de) | N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten | |
DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
KR970703353A (ko) | 단핵구 주화성 단백질-4(monocyte chemotactic protein-4) | |
DK0846173T3 (da) | Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma | |
DE69629023D1 (de) | Piperazino-derivative als neurokininantagonisten | |
CY1105548T1 (el) | Συνδυασμος του loteprednol και αγωνιστων του β2-αδρενοϋποδοχεως και η χρηση του με εισπνοες για την αγωγη του βρογχικου ασθματος | |
FR2804027B1 (fr) | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers | |
SE9801368D0 (sv) | New use | |
AU2003240790A1 (en) | Antibody peg positional isomers, compositions comprising same, and use thereof | |
ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen | |
DE502004012439D1 (de) | Medikament und verwendung zur tumortherapie | |
YU1901A (sh) | Upotreba nab1 i nab2 u farmaciji |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R082 | Change of representative |
Ref document number: 1159003 Country of ref document: EP Representative=s name: BUSSE & BUSSE PATENT- UND RECHTSANWAELTE PARTNERSC |
|
R097 | No opposition filed against granted patent, or epo opposition proceedings concluded without decision |
Ref document number: 1159003 Country of ref document: EP Effective date: 20110818 |